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Objective: The aim of the present study was to evaluate whether vitamin D status is related to blood
pressure (BP) in adults.
Methods: We evaluated the relationship between vitamin D status, intact parathyroid hormone
(iPTH) and BP in 332 adults. Anthropometric measurements, BP, and a fasting blood sample was
obtained. Participants were stratiﬁed into the following BP categories: 1) normal BP; 2) high BP; 3)
normal BP through medication. Vitamin D insufﬁciency was deﬁned as 25-hydroxvitamin D  75
nmol/L; high iPTH as > 65 pg/mL. The relationships between vitamin D status, iPTH and BP were
adjusted for bodymass index, waist circumference, blood lipids, physical activity, and sunscreen use.
Results: No differences in prevalences of vitamin D insufﬁciency and high iPTH were observed
among BP groups. No signiﬁcant association was observed between BP and vitamin D status.
Positive correlations were observed between iPTH and systolic BP (r ¼ 0.168; P ¼ 0.002) and
between iPTH and diastolic BP (r ¼ 0.168; P ¼ 0.002). iPTH remained correlated with BP even with
adjustments.
Conclusions: The present study contributes to the understanding of calcemic hormones and BP
regulation.
 2013 Elsevier Inc. All rights reserved.Introduction
Hypertension remains a major risk factor for cardiovascular
disease (CVD). About 1 billion people worldwide suffer from
hypertension, and this may be responsible for approximately 7.1
million deaths per year [1]. Recently, the Brazilian Society of
Hypertension [2] published data showing that in 2007, approx-
imately 309,000 deaths were caused by CVD and that the esti-
mated prevalence of hypertension was greater than 30%.
According to theWorld Health Organization (WHO) [3], CVDs are
the leading cause of death globally and by 2030, 23.6 million
people will die from this illness.
There is much evidence to show that vitamin D is involved in
several mechanisms in addition to bone metabolism [4]. Vitamin
D insufﬁciency/deﬁciency has been associated with hyperten-
sion worldwide [5–7] and with the cardiovascular complications
of hypertension [8–10]. As depicted in a recent review [11],
vitamin D may be involved in regulation of gene expression: þ55 11 30617731.
tini).
ll rights reserved.through the presence of vitamin D receptors in various cells.
Regarding the regulation of blood pressure (BP), there is
evidence that 25-hydroxyvitamin D (25[OH]D) acts through the
renin–angiotensin system, as well as through modulation of cell
growth and proliferation, including vascular smooth muscle cells
and cardiomyocytes.
Moreover, several studies have observed vitamin D insufﬁ-
ciency/deﬁciency even in sunny countries, especially in adults
and the elderly [12,13]. Factors that reduce its synthesis, such as
high levels of air pollution and low levels of outdoor activities,
may be the cause of this situation. Nevertheless, the effects of
vitamin D insufﬁciency/deﬁciency on BP have not been evaluated
in Brazilian populations.
Thus, the aim of the present study was to evaluate whether
vitamin D status is related to BP in adults.Participants and methods
Study design
This cross-sectional study was conducted among non-institutionalized
adults attending a public primary care unit linked to the School of Public
Table 1
General characteristics of the whole sample
Variable Whole
sample
Normal
blood
pressure
High blood
pressure
Normal blood
pressure
through
medication
P-value
Participants (n) 332 166 112 54
Age (y) 50 (15) 42 (13) 57 (14)* 59 (11)* 0.000
BMI (kg/m2) 29 (6) 27 (5) 30 (6)* 31 (6)* 0.000
%FFM 68 (10) 69 (10) 67 (9) 65 (9)* 0.015
%FM 32 (10) 31 (10) 33 (9) 35 (9)* 0.015
Waist
circumference
(cm)
97 (13) 92 (13) 101 (14)* 100 (12)* 0.000
Gender (%)
Male 38 38 45 24
Female 62 62 55 76
Systolic BP
(mm Hg)
129 (18) 118 (11) 148 (14)* 125 (9)*,y 0.000
Diastolic BP
(mm Hg)
80 (11) 74 (8) 89 (11)* 77 (7)*,y 0.000
Total cholesterol
(mg/dL)
190 (41) 184 (41) 198 (42)* 193 (39) 0.022
LDL-C (mg/dL) 120 (37) 117 (37) 125 (37) 118 (36) NS
HDL-C (mg/dL) 43 (12) 43 (11) 43 (12) 44 (11) NS
Triacylglycerol
(mg/dL)
134 (76) 122 (77) 146 (79)* 148 (57)* 0.009
Glucose (mg/dL) 93 (11) 91 (11) 94 (13) 97 (12)* 0.006
Vitamin D
insufﬁciency (%)
86 88 84 87 NS
High PTH (%) 12 10 14 13 NS
%FM, percent body fat mass; %FFM; percent body fat-free mass; BMI, body mass
index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; PTH, parathyroid hormone
Data are mean (SD) for continuous variables and % for categorical variables. High
PTH was deﬁned as > 65 pg/mL; vitamin D insufﬁciency was deﬁned as < 75
nmol/L
* Signiﬁcant when compared with normal BP group (P < 0.05).
y Signiﬁcant when compared with high BP group (P < 0.05).
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protocol, and all participants signed an informed consent statement.
The exclusion criteria were that the participants could not be younger than
age 18 y; could not be pregnant or lactating; and could not have had previous
cardiovascular events or diseases that might modify their vitamin D metabolism
(chronic kidney disease, neoplasia, diabetes, or osteoporosis). Black individuals;
individuals with abnormal concentrations of creatinine, calcium, or phosphorus;
and those who reported using vitamin D and/or calcium or multivitamin
supplements were also excluded.
A sample of 460 individuals was screened between August 2007 and January
2010; 128 were excluded due to diabetes mellitus (n ¼ 57) or abnormal creati-
nine, calcium, or phosphorus (n ¼ 19). Six individuals presented outlying serum
concentrations of parathyroid hormone (PTH); 1 had outlying serum concen-
trations of 25(OH)D and another 45 fulﬁlled other exclusion criteria. Thus, 332
individuals who agreed to participate were included in this analysis.
Measurements
Height was measured using a ﬁxed stadiometer with a vertical backboard
and movable headboard, with participants standing on the ﬂoor. Weight was
taken by asking each individual to stand at the center of the platform of a Tanita
digital scale (Tanita Corporation of America Inc., Illinois, USA). Body mass index
(BMI ¼ weight [kg]/height [m]2) was calculated. Waist circumference (WC) was
measured while participants were standing up, with a tape placed at the
midpoint level between the lower intercostal border and the anterior superior
iliac supine as the participants were gently exhaling. Percent body fat mass (%FM)
and percent body fat-free mass (%FFM) were assessed by means of tetrapolar
bioelectrical impedance analysis (Quantum BIA 101Q, RJL, Detroit, USA).
BP was obtained using an automatic BP monitor (Omron model HEM-712C,
Omron Health Care, Inc., USA). Three measures were taken at rest in a sitting
position, with intervals of 5 min between the measurements. The average from
the last two measurements was taken for analysis. The participants were strat-
iﬁed into categories: 1) normal BP (NBP): those with systolic/diastolic BP
(SBD/DBP)  140/90 mm Hg; 2) high blood pressure (HBP): taken to be indi-
viduals with BP 140/90mmHg; and 3) normal BP throughmedication (NBPM):
when individuals had normal BP achieved through pharmacological treatment.
After 12 h of fasting, a blood sample was collected from each individual, and
was frozen and stored at 80C until analysis. Serum triacylglycerol, total
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipo-
protein cholesterol (HDL-C), and glucose were determined by enzymatic colori-
metric assay (Celm, Barueri, SP, Brazil), and creatinine was determined using
a colorimetric assay (Celm, Barueri, SP, Brazil). Calcium and phosphorus were
determined using another colorimetric assay (Bioclin, Belo Horizonte, MG,
Brazil). Serum concentrations of 25(OH)D were measured by high-performance
liquid chromatography (Immundiagnostik AG, Bensheim, Germany) with intra-
assay coefﬁcients of variation (CVs) of 5.2% and inter-assay CVs of 8.4%. The
serum concentrations of intact PTH (iPTH) were measured using an electro-
chemiluminescence assay (Roche Diagnostics, S~ao Paulo, SP, Brazil), the intra-
assay and inter-assay were both 6% with a reference range of 15 to 65 pg/mL.
High PTH was deﬁned as serum concentrations of PTH > 65 pg/mL. Serum
25(OH)D concentrations < 75 nmol/L were deﬁned as cases of insufﬁciency [14].
The individuals alsowere asked about the regular physical exercise and use of
sunscreen.
Statistical analysis
The results were expressed as means and SDs. Statistical analyses were
performed using the Statistical Package for the Social Sciences, version 17.0
(SPSS Inc., Chicago, USA). The signiﬁcance level taken was 5%. Some skewed
variables were log-transformed to obtain normal distribution (PTH, BMI,
triacylglycerol, and HDL-C).
Analysis of variance (ANOVA) was used to evaluate differences between BP
categories. Associations of 25(OH)D and PTH with covariates were examined
using Pearson’s correlation.
In secondary analysis, we also investigated whether the associations among
vitamin D status, iPTH, and BP were confounded by physical activity, sunscreen
use, and other clinical conditions, for example dyslipidemia (TC, LDL-C, and tri-
acylglycerol) and obesity (BMI andWC). For this, twomodels were built: model 1
included adjustments for physical activity, sunscreen use, blood lipids (TC, LDL-C,
and triacylglycerol) and BMI; in model 2, WC replaced BMI. To evaluate possible
interference of pharmacologic treatment in these analyses, we performed the
same correlations without participants under antihypertensive medication.
Finally, to better display the associations between PTH and BP, we performed the
correlation analysis without individuals with high PTH.
Multiple linear regression models were used for testing 25(OH)D and iPTH as
continuous variables for predicting SBP and DBP with thewhole sample and then
without individuals under hypertension treatment.Results
High BP was present in 34% of the whole sample, and another
16% were taking medication for hypertension. Overweight and
obesity (WHO, 1997) was present in 75% of the individuals. Only
23% of whole sample reported practice regular physical exercise
and the use of sunscreen was present in 22% of individuals. The
general characteristics of the whole sample and in the different
subsamples are presented in Table 1. As expected, BMI, WC,
glucose, and triacylglycerol were signiﬁcantly higher in indi-
viduals with high BP and in those who were under hypertension
treatment. No differences were observed regarding the preva-
lence of vitamin D insufﬁciency and high PTH among the BP
groups.
Table 2 shows the serum concentrations of 25(OH)D and
other calcemic hormones in the whole sample and in each BP
group. The serum iPTH concentrations were signiﬁcantly higher
in individuals with high BP than in individuals with normal BP.
No signiﬁcant association was observed between the
concentrations of 25(OH)D and BP. However, vitamin D status
was positively associated with TC (r ¼ 0.479; P ¼ 0.000), LDL-C
(r ¼ 0.360; P ¼ 0.000) and log triacylglycerol (r ¼ 0.491; P ¼
0.000). From analysis on associations between 25(OH)D and BP
with adjustments, no correlationwas observed either in model 1
or in model 2.
On the other hand, positive correlations were observed
between iPTH and the following: SBP (r ¼ 0.168; P ¼ 0.002), DBP
(r ¼ 0.168; P ¼ 0.002), BMI (r ¼ 0.125; P ¼ 0.023), WC (r ¼ 0.172;
P ¼ 0.002), and %FM (r ¼ 0.158; P ¼ 0.004). There was a negative
Table 2
Mean serum concentration of calcemic hormones in the whole sample and in each blood pressure group
Variable Whole sample
(N ¼ 332)
Normal blood pressure
(n ¼ 166)
High blood pressure
(n ¼ 112)
Normal blood pressure through
medication (n ¼ 54)
P-value
25(OH)D3 (nmol/L) 55.8 (17.1) 55.6 (17.7) 56.4 (17.4) 55.3 (15.0) NS
PTH (pg/mL) 40.8 (18.7) 37.7 (17.7) 44.3 (18.6)* 43.0 (20.4) 0.006
Serum calcium (mg/dL) 9.3 (0.5) 9.2 (0.5) 9.4 (0.4)* 9.4 (0.5) 0.004
Serum phosphorus (mg/dL) 3.7 (0.7) 3.7 (0.7) 3.6 (0.8) 3.7 (0.9) NS
25(OH)D3, 25-hydroxyvitamin D3; PTH, parathyroid hormone
Data are means (SD)
* Signiﬁcant when compared with normal blood pressure group (P < 0.05).
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Furthermore, when the data were adjusted, in model 1, the
associations between PTH and SBP (r ¼ 0.157; P ¼ 0.005) and
between PTH and DBP (r ¼ 0.139; P ¼ 0.014) were maintained,
and a negative association was observed between PTH and
vitamin D status (r ¼ 0.137; P ¼ 0.015). After adjustment, in
model 2, the same associations occurred: positive with SBP (r ¼
0.146; P ¼ 0.010) and DBP (r ¼ 0.126; P ¼ 0.026) and negative
with vitamin D status (r ¼ 0.133; P ¼ 0.019).
In a multiple linear regression model (Table 3), iPTH and BMI
could only account for 5% of the variation in SBP and 10% of the
variation in DBP.
When individuals taking medication for hypertension (n ¼
54) were excluded from the analysis, signiﬁcant correlations
were found between iPTH and SBP (r ¼ 0.194; P ¼ 0.001), DBP
(r ¼ 0.211; P ¼ 0.001), and WC (r ¼ 0.147; P ¼ 0.015). In the
secondary analysis, including adjustment for BMI (model 1),
vitamin D status was negatively correlated, but not signiﬁcantly,
with SBP (r ¼ 0.114; P ¼ 0.067), whereas iPTH remained
essentially unaltered, with positive correlations with SBP
(r ¼ 0.185; P ¼ 0.003) and DBP (r ¼ 0.188; P ¼ 0.002). The
same correlations appear when analysis was adjusted for WC
(model 2).
Thus, in a multiple linear regression (Table 4), the model can
explain approximately 6% of the variation in SBP and 13% of the
variation in DBP, of the individuals who were not under hyper-
tension treatment.
In the last analysis, individuals with high PTH (n ¼ 40) were
excluded and the same correlations between iPTH and SBP (r ¼
0.175; P ¼ 0.003) and DBP (r ¼ 0.151; P ¼ 0.009) were observed.
These correlations remain signiﬁcant when the analysis was
performed with adjustments.Table 3
Regression coefﬁcients (B) for PTH (pg/dL), 25(OH)D3 (nmol/L) and BMI (kg/m2)
regressed against blood pressure in whole sample (N ¼ 332)
Systolic BP Diastolic BP
B (SE) B R2 B (SE) B R2
Step 1
Constant 55.39 (18.10) 11.53 (10.50)
Vitamin D 0.06 (0.06) 0.06 0.05 (0.03) 0.08
iPTH 13.70 (4.76) 0.16* 7.36 (2.76) 0.14*
BMI 33.62 (11.97) 0.15* 0.06 36.88 (6.94) 0.28* 0.11
Step 2
Constant 57.71 (18.00) 13.48 (10.45)
iPTH 13.11 (4.73) 0.15* 6.87 (2.75) 0.13y
BMI 35.07 (11.90) 0.16* 0.05 38.10 (6.92) 0.29* 0.10
BMI, body mass index; BP, blood pressure; iPTH, intact parathyroid hormone;
PTH, parathyroid hormone
* P < 0.01.
y P < 0.05.Discussion
In the present study, PTH was associated with elevated BP,
whereas vitamin D status was not correlated with BP even after
exclusion of individuals under treatment for hypertension and
adjustment for physical activity, sunscreen use, blood lipids, and
BMI or WC. Hellstrom et al. (1958) ﬁrst described the association
between elevated serum concentrations of PTH and hyperten-
sion in individuals with hyperparathyroidism [15]. Over the
years, the contribution of PTH toward raised BP has been
observed even in individuals with PTH within the normal range
[16–18]. Another study [19] reported that individuals with
higher PTH also were at greater risk for cardiovascular mortality,
evenwhen the data were adjusted for established cardiovascular
risk factors. Moreover, this association remained present in
individuals with PTHwithin the normal range. Like these studies,
PTH in our study was positively correlated with BP, and this
association also was observed among individuals with PTH
within the normal range even after adjustments. Additionally, all
individuals had serum calcium within the normal range.
However, in a study performed with Chinese population [20],
PTH was associated with BP and risk for hypertension, but this
association became non-signiﬁcant after adjustments.
More recently, in cross-sectional data from National Health
and Nutrition Examination Survey (NHANES) 2003–2006,
researchers [21] found that PTH was positively correlated with
BP and, when PTH was divided into quintiles, the SBP and DBP
were 5.9 and 4.5 mm Hg higher, respectively, in the highest
quintile of PTH ( 59 ng/L) than in the lowest quintile ( 27
ng/L). These authors suggested that PTH might modulate the
relationship between vitamin D status and BP. Among older
Chinese men, one study [22] reported that increased PTHTable 4
Regression coefﬁcients (B) for PTH (pg/dL), 25(OH)D3 (nmol/L) and BMI (kg/m2)
regressed against blood pressure in the individuals without medication for
hypertension (n ¼ 278)
Systolic BP Diastolic BP
B (SE) b R2 B (SE) B R2
Step 1
Constant 40.06 (20.92) 0.06 (11.95)
Vitamin D 0.06 (0.07) 0.05 0.04 (0.40) 0.07
iPTH 16.92 (5.58) 0.18* 10.07 (3.19) 0.18*
BMI 41.75 (14.01) 0.18* 0.06 42.35 (8.00) 0.30* 0.11
Step 2
Constant 40.85 (20.89) 1.21 (11.94)
iPTH 16.54 (5.56) 0.18* 9.77 (3.18) 0.17
BMI 43.78 (13.80) 0.18* 0.06 43.93 (7.89) 0.32 0.13
BMI, body mass index; BP, blood pressure; iPTH, intact parathyroid hormone;
PTH, parathyroid hormone
* P < 0.01.
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quartile of PTH presented SBP and DBP, respectively, 3.4 and 2.8
mm Hg higher than men in lowest quartile.
Vitamin D insufﬁciency present in our sample, 86%, should
reﬂect besides the lowoutdoor activity, the low vitamin D intake,
once that, in our country, the food fortiﬁcation with vitamin D is
not mandatory and the principal foods that contains this vitamin
is not present in our dietary habits.
Although several studies have suggested that low concen-
trations of 25(OH)D are associated with higher BP [5,23], no
associationwas observed between vitamin D status and BP in our
sample. In older Chinese men [22] no associations were found
between vitamin D and BP, however, in this study, the partici-
pants evaluated had optimal vitamin D concentrations.
Also in relation to data from NHANES 2003–2006 [21], the
authors found values for SBP and DBP that were respectively 3.5
and 1.8mmHg lower in the highest quintile of vitamin D (25[OH]
D  75 nmol/L) than in the lowest quintile (25[OH]D  32.5
nmol/L). These ﬁndings are similar to the results from a previous
study also performed with participants from NHANES III [6]. This
negative relationship between serum concentration of 25(OH)D
and hypertension was also demonstrated in the Nurses’ Health
Study and the Healthy Professional Follow-up Study [24]. In the
present analysis, a tendency toward a negative association
between vitamin D status and SBP was only present in individ-
uals who were not using medication for hypertension and with
adjustment for blood lipids and BMI or WC. This could indicate
some kind of interaction between these medications and
mechanisms for vitamin D metabolism, thus confounding the
association between it and BP. Although our sample was
composed of many obese individuals, adjustments for blood
lipids and WC removed the effect of obesity (factor that is well
established as leading to development of hypertension).
There are threemainmechanisms thatmay explain the role of
PTH in regulating BP. It could act on cardiomyocytes to promote
left ventricular hypertrophy [25,26] and chronotropic effects on
pacemaker cells [27] producing immediate and sustained rise in
heart beats [28]. Intracellular calcium seems to be involved in
this mechanism, but the evidences are conﬂicting [27,29].
Furthermore, the high serum concentrations of PTH seem to lead
the exposed cardiac cells to premature death [28]. Another
mechanism through which PTH can interfere in BP consists of
structural and functional modiﬁcations to the vascular wall,
promoted by PTH through alterations in endothelium and
vascular smooth muscle cells, given that PTH receptor have been
described in these cells [30]. Finally, some evidence has shown
that PTH could be involved in inﬂammatory response mediated
production of interleukin-6 by osteoblasts and, possibly, by
adipocytes [31]. Additionally, PTH has been positively correlated
with ﬁbrinogen, C-reactive protein, [31] and leptin [32].
The role of PTH in regulating mineral metabolism is well
recognized. Increases in PTH could be indicative of other disor-
ders such as vitamin D deﬁciency [33], hyperphosphatemia,
hypercalcemia, or chronic kidney disease (conditions that are
known to lead to cardiovascular complications and higher risk
for mortality). In our study, we sought to remove the patients
who presented such conditions, except for vitamin D insufﬁ-
ciency. In addition the negative correlation between PTH and
vitamin D status observed, 10% of our sample presented both
high PTH and low vitamin D status.
It is important to emphasize that the prevalence of over-
weight and obesity among the participants was found to be very
high (75%). Likewise, the WC measurements were large (such
measurements have been linked with abdominal obesity) andthe TC, LDL-C, and triacylglycerol concentrations were high.
These conditions, as well as hypertension, are strong risk factors
for CVD, and together reﬂect a serious problem in our environ-
ment that deserves attention.
The present study has some limitations. Because it had
a cross-sectional design, these results do not allow us indicate
causality and temporal associations. Furthermore, low concen-
trations of 25(OH)D in all groups may have been the cause of null
interactions between them. These concentrations of 25(OH)D
and the lack of association with BP lead us to question the real
cutoff point that should be considered for classifying individuals
with vitamin D insufﬁciency when the aim is to establish
a predictor for CVD in our population. From this point of view,
the number of participants, and their conditions, like the high
percentage of overweight and obese, as well the vitamin D
classiﬁcation based on bone metabolism effects, may not have
been sufﬁcient to establish the association between vitamin D
status and BP. Additionally, the role of inﬂammation through
increased PTH should be further investigated.
Conclusions
In summary, the association between PTH and BP observed in
this study contributes to the understanding of calcemic
hormones and BP regulation. The metabolic pathway that causes
this disorder needs further investigation in clinical and
prospective studies in order to better characterize and elucidate
the relationship between them.
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